UnitedHealthcare respiratory pathogen panels Coverage

Coverage Criteria and Clinical Guidance

Outpatient multiplex panels (Not medically necessary)

Covered or not covered guidance

Outpatient multiplex panels: Respiratory pathogen panel testing of six or more targets in an outpatient setting is unproven and not medically necessary due to insufficient evidence of efficacy for outpatient indications.>=6 targets

Policy applies to Pennsylvania outpatient testing; individual exceptions may be evaluated case-by-case per Pennsylvania Code Title 55, Chapter 1101.

Appropriate use populations

Populations/environments where testing may be appropriate

High-risk or inpatient settings: Multiplex respiratory panel testing may be appropriate for certain high-risk populations or inpatient settings such as hematology/oncology, transplant, ICU patients, and pediatric patients with underlying illness, and for hospitalized or severely ill patients per society guidance.

Guidelines (ASM, ATS, IDSA) support selective use in these populations.

Clinical testing recommendations

Coverage guidance aligned to cited guideline recommendations:

Outpatient and immunocompetent non-severe CAP: Routine NAA/NAAT testing for non-influenza respiratory pathogens is conditionally recommended against.

Based on ATS guideline noting no significant impact on key outcomes (overall survival, antibiotic use).

Hospitalized patients: For hospitalized patients with severe community-acquired pneumonia (CAP) or those in intensive care units, comprehensive/multiplex respiratory panel testing is suggested to guide antimicrobial therapy.

IDSA recommends comprehensive panels in hospitalized/ICU patients to inform management.

Immunocompromised patients: Consider NAA/NAAT testing for non-influenza respiratory pathogens in immunocompromised individuals where results would alter management.

ATS suggests testing in immunocompromised patients; use guided by clinical impact on management.

Outpatient respiratory pathogen panels that detect six or more targets are excluded from coverage because they are considered unproven and not medically necessary for routine outpatient use. The policy determination reflects insufficient evidence of clinical efficacy in outpatient populations, concerns about prolonged viral shedding, multiple positive results or coinfections, variable accuracy across panel targets, and low-quality supportive studies. Individual exceptions for Pennsylvania members may be evaluated case‑by‑case per applicable state or contractual terms.

Information from the U.S. Food and Drug Administration is provided for reference only. FDA approval alone is not a basis for coverage; clearance or approval of a device does not, by itself, establish medical necessity under this policy.

This policy restates that respiratory pathogen panel testing performed in the outpatient setting that includes six or more targets is considered not medically necessary due to inadequate evidence that such large fixed multiplex panels improve management or outcomes compared with targeted testing.

Routine nucleic acid amplification (NAA) testing for non‑influenza respiratory viruses is not recommended for outpatients and for immunocompetent inpatients with non‑severe suspected community‑acquired pneumonia; guideline authors conditionally recommend against routine testing in these groups because NAA testing has not demonstrated meaningful impact on key outcomes such as survival or antibiotic use.

When Multiplex Testing May Be Appropriate (Covered Indications)

Hospitalized or severely ill patients and high-risk populations (hematology/oncology, transplant, ICU, pediatric with underlying illness).

Hospitalized or severely ill patients and high‑risk populations (hematology/oncology, transplant recipients, ICU patients, and pediatric patients with underlying illness) are appropriate candidates for multiplex respiratory panel testing when results are expected to influence clinical management.

ASM identifies these groups as appropriate candidates; apply testing when results will alter treatment decisions.

Hospitalized patients with severe CAP, ICU patients, or immunocompromised individuals where results would alter management

Severe CAP, ICU, or immunocompromised: For hospitalized patients with severe community-acquired pneumonia (CAP), patients in the intensive care unit, or immunocompromised individuals, perform comprehensive/multiplex NAA/NAAT respiratory testing when detection of non-influenza pathogens would alter antimicrobial or other clinical management.

ATS suggests considering NAA testing in severe or immunocompromised cases; IDSA supports comprehensive panels in hospitalized/ICU patients to guide therapy.

Services Not Covered / Considered Not Medically Necessary

Respiratory pathogen panel testing that includes six or more targets and is ordered for outpatient settings is not covered by this policy and is considered not medically necessary. Requests for such outpatient panels may be denied unless documentation demonstrates a specific, medically necessary rationale consistent with applicable benefit terms.

Routine NAA testing for non‑influenza respiratory pathogens is not recommended for outpatients and for immunocompetent inpatients with non‑severe suspected community‑acquired pneumonia. For hospitalized patients who are severely ill or immunocompromised, NAA testing may be considered per guideline recommendations.

Procedure Codes and Panel Thresholds

Referenced PLA Codes (examples)mixed

0115U	Respiratory infectious agent detection by nucleic acid (DNA and RNA), 18 viral types and subtypes and 2 bacterial targets, amplified probe technique, including multiplex reverse transcription for RNA targets, each analyte reported as detected or not detected.
0202U	Infectious disease (bacterial or viral respiratory tract infection), pathogen-specific nucleic acid (DNA or RNA), 22 targets including severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), qualitative RT-PCR, nasopharyngeal swab, each pathogen reported as detected or not detected.
0223U	Infectious disease (bacterial or viral respiratory tract infection), pathogen-specific nucleic acid (DNA or RNA), 22 targets including severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), qualitative RT-PCR, nasopharyngeal swab, each pathogen reported as detected or not detected.

Referenced CPT/PLA Codesmixed

0225U	Infectious disease (bacterial or viral respiratory tract infection) pathogen-specific DNA and RNA, 21 targets, including severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), amplified probe technique, including multiplex reverse transcription for RNA targets, each analyte reported as detected or not detected.
0556U	Infectious disease (bacterial or viral respiratory tract infection), pathogen-specific DNA and RNA by real-time PCR, 12 targets, nasopharyngeal or oropharyngeal swab, including multiplex reverse transcription for RNA targets, each analyte reported as detected or not detected.
0563U	Infectious disease (bacterial and/or viral respiratory tract infection), pathogen-specific nucleic acid (DNA or RNA), 11 viral targets and 4 bacterial targets, qualitative RT-PCR, upper respiratory specimen, each pathogen reported as positive or negative.
0564U	Infectious disease (bacterial and/or viral respiratory tract infection), pathogen-specific nucleic acid (DNA or RNA), 10 viral targets and 4 bacterial targets, qualitative RT-PCR, upper respiratory specimen, each pathogen reported as positive or negative.
87632	Infectious agent detection by nucleic acid (DNA or RNA); respiratory virus (e.g., adenovirus, influenza virus, coronavirus, metapneumovirus, parainfluenza virus, respiratory syncytial virus, rhinovirus), includes multiplex reverse transcription, when performed, and multiplex amplified probe technique, multiple types or subtypes, 6-11 targets.
87633	Infectious agent detection by nucleic acid (DNA or RNA); respiratory virus (e.g., adenovirus, influenza virus, coronavirus, metapneumovirus, parainfluenza virus, respiratory syncytial virus, rhinovirus), includes multiplex reverse transcription, when performed, and multiplex amplified probe technique, multiple types or subtypes, 12-25 targets.

Panel target count threshold (six or more targets)

ThresholdPanels with six or more targets are identified as unproven and not medically necessary in outpatient settings.

Numeric value>= 6 targets

ScopeApplies to outpatient respiratory pathogen panel testing in Pennsylvania; individual exceptions evaluated case-by-case per Pennsylvania Code Title 55, Chapter 1101.

Provider Responsibilities, Documentation, and Billing Impact

Prior Authorization

Prior Authorization Required

Prior authorization is required for outpatient multiplex respiratory pathogen panels that include six or more targets. Submit documentation that demonstrates medical necessity and that less broad, targeted testing was considered or attempted when clinically appropriate.

Panels with >=6 targets in outpatient setting may be denied without prior authorization
Provide clinical rationale for testing breadth and how results will impact management

Documentation Required

Coding and Documentation Requirements

Document the specific clinical indication, signs/symptoms, patient risk factors (e.g., immunocompromised status, ICU admission, transplant or oncology care), and how results will change management. Include the exact procedure code(s) billed and attach relevant clinical notes or orders.

Reference applicable procedure codes from policy (e.g., 0115U, 0202U, 0223U, 0225U, 0556U, 0563U, 0564U, 87632, 87633) on the claim and in supporting documentation

Ordering and Prioritization of Tests

Step Therapy

Order consistent with clinical guideline recommendations

Order multiplex panels in accordance with clinical guidelines: reserve them for hospitalized, severely ill, or high‑risk patients and avoid routine use in otherwise healthy outpatients.

ATS conditionally recommends against routine NAA testing for non‑influenza viruses in outpatients and immunocompetent non‑severe CAP patients.
IDSA and ASM identify hospitalized, ICU, transplant, oncology, and certain pediatric patients as appropriate populations for multiplex testing.

Documentation Required

Ensure orders comply with member benefit terms

Ordering and coverage decisions must align with the member's federal, state, or contractual benefit terms; this policy does not define who is authorized to order tests.

Confirm allowable orderers and benefit coverage per the specific plan; policy is informational and not a substitute for plan rules.

Definitions

Respiratory pathogen panel (RPP) definition

DefinitionA multiplex nucleic acid amplification assay that detects multiple respiratory pathogens (viruses, bacteria, fungi, and sometimes resistance genes) from a single respiratory specimen, often using PCR-based technology.

Specimen and methodOften performed on upper respiratory specimens using PCR or other NAAT technologies to detect multiple analytes simultaneously.

Clinical noteMay produce results more rapidly than traditional methods (culture, serology) and can include detection of antibiotic-resistance genes.

nucleic acid amplification test / nucleic acid amplification (NAA/NAAT) definition

DefinitionNucleic acid amplification test (NAA/NAAT): molecular methods (eg, PCR-based) that amplify and detect pathogen nucleic acids (DNA or RNA) in respiratory specimens.

Clinical guidance

Background and Rationale

Acute respiratory infections are common and are most frequently caused by viral pathogens. Multiplex nucleic acid amplification tests (NAATs), often called respiratory pathogen panels (RPPs), detect multiple viral and sometimes bacterial targets from a single respiratory specimen and can provide rapid identification compared with traditional methods. However, the clinical utility of large multiplex panels in outpatient populations is uncertain because prolonged shedding, coinfections, variable per‑target accuracy, and limited high‑quality outcome data complicate interpretation and have not demonstrated consistent improvement in patient management or outcomes.

Frequency Limits

Frequency limits — not specified

Frequency limitsNot specified in this part of the document.

ApplicabilityPolicy applies to services in Pennsylvania; frequency rules are not provided here and may be governed by member contract or separate guidance.

ActionIf needed, frequency limits should be checked against the member's benefit documents or laboratory-specific policies.

Frequency limit (unspecified)

Frequency limit placeholderNo frequency limit specified in this document section.

Next stepsRefer to the member's federal, state, or contractual benefit terms for any applicable frequency restrictions or prior authorization requirements.

OpenPayer

Respiratory Pathogen Nucleic Acid Detection Testing (for Pennsylvania Only)